Oral Session 1-7D Multiple Myeloma: Novel Agents

[OS1-7D-2] A phase 3 study of isatuximab, pomalidomide & dexamethasone in relapsed/refractory multiple myeloma

Kenshi Suzuki¹, Paul G. Richardson², Michel Attal³, Jesus San-Miguel⁴, Meral Beksac⁵, Ivan Spicka⁶, Xavier Leleu⁷, Fredrik Scjesvold⁸, Philippe Moreau⁹, Meletios A. Dimopoulos¹⁰, Jeffrey_Shang-Yi Huang¹¹, Jiri Minarik¹², Michele Cavo¹³, H._Miles Prince¹⁴, Sandrine Mace¹⁵, Kathryn P. Corzo¹⁶, Frank Campana¹⁶, Solenn Le-Guennec¹⁵, Franck Dubin¹⁵, Kenneth_C. Anderson² (1.Japanese Red Cross Medical Center, Shibuya City, Tokyo, Japan, 2.Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, United States of America, 3.Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, France, French Republic, 4.Clinica Universidad de Navarra, Navarra, Spain, Spain, 5.Ankara University, Ankara, Turkey, Republic of Turkey, 6.Charles University in Prague, Prague, Czech Republic, Czech Republic, 7.Hopital Claude Huriez, CHRU Lille, Lille, France, French Republic, 8.Oslo Myeloma Center, Oslo University Hospital, and KG Jebsen Center for B Cell Malignancies, University of Oslo, Oslo, Norway, Kingdom of Norway, 9.CHU Nantes, Nantes, France, French Republic, 10.National and Kapodistrian University of Athens, Athens, Greece, Hellenic Republic, 11.National Taiwan University Hospital, Taipei, Taiwan, Taiwan, 12.University Hospital Olomouc, Olomouc, Czech Republic, Czech Republic, 13.Univeristy of Bologna, Bologna, Italy, Italian Republic, 14.Epworth Healthcare and Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Victoria, Australia, 15.Sanofi R & D, Vitry-Alfortville, France, French Republic, 16.Sanofi-Genzyme Oncology, Cambridge, MA, United States of America)